

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Cortef 10 mg Tablet (DIN 00030910) manufactured by Pfizer Canada ULC, Cortef 10 mg Tablet (DIN 09858155) manufactured by Pfizer Canada ULC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pfizer Canada ULC has advised Alberta Blue Cross® that the shortage of Cortef 10 mg Tablet (DIN 00030910) has been resolved.

As a result, Cortef 10 mg Tablet (DIN 09858155) will no longer be considered a temporary benefit for the *ADBL* **after January 10, 2023**. The above grouping was removed from the Critical Supply Product List **December 2, 2022**.

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Hydromorphone 2 mg/mL Injection (DIN 02145901) manufactured by Sandoz Canada Inc., Hydromorphone HCL 2 mg/mL Injection (DIN 02460602) manufactured by Sterimax Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 19, 2022**.

As of **December 19, 2022**, all claims for Hydromorphone HCL 2 mg/mL Injection (DIN 02460602) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Due to the unavailability of Pediatrix 80 mg/mL Oral Drops (DIN 02027801) manufactured by Teva Canada Limited, Infants' Tylenol 80 mg/mL Oral Drops (DIN 02389908) manufactured by McNeil Consumer Healthcare will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 6, 2022**.

As of **December 6, 2022**, all claims for Infants' Tylenol 80 mg/mL Oral Drops (DIN 02389908) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Due to the unavailability of Teva-Codeine 15 mg Tablet (DIN 00593435) and Teva-Codeine 30 mg Tablet (DIN 00593451) manufactured by Teva Canada Limited, Codeine 30 mg Tablet (DIN 02009757) manufactured by Laboratoire Riva Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 6, 2022**.

As of **December 6, 2022**, all claims for Codeine 30 mg Tablet (DIN 02009757) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php.

continued next page

PHARMACY BENEFACT

continued from previous page

Due to the unavailability of Teva-Cephalexin 125 25 mg/mL Oral Suspension (DIN 00342106) manufactured by Teva Canada Limited, Lupin-Cephalexin 25 mg/mL Oral Suspension (DIN 02469170) manufactured by Lupin Pharma Canada Limited will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was previously added to the Critical Supply Product List **December 9, 2022**.

As of **December 14, 2022**, all claims for Lupin-Cephalexin 25 mg/mL Oral Suspension (DIN 02469170) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Dr Reddys Laboratories Canada Inc. that the shortage for Zoledronic Acid 5mg/100mg Injection (DIN 02422433) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 9, 2023**. The following grouping was removed from the Critical Supply Product List **December 8, 2022**.

ZOLEDRONIC ACID

0.05 MG / ML INJECTION

| | | | |
|-------------|----------------------|-----|-----------|
| 00002415100 | TARO-ZOLEDRONIC ACID | TAR | \$ 3.3540 |
| 00002422433 | ZOLEDRONIC ACID | DRL | \$ 3.3540 |
| 00002269198 | ACLASTA | NOV | \$ 7.1629 |

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Fesoterodine Fumarate 8 mg Extended-Release Tablet (DIN 02521776) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 10, 2023**. The following grouping was removed from the Critical Supply Product List **December 9, 2022**.

FESOTERODINE FUMARATE

8 MG EXTENDED-RELEASE TABLET

| | | | |
|-------------|------------------------------|-----|-----------|
| 00002521776 | SANDOZ FESOTERODINE FUMARATE | SDZ | \$ 1.1250 |
| 00002380048 | TOVIAZ | PFI | \$ 1.5000 |

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

